...
首页> 外文期刊>Human Genetics >Mutational analysis of the CCR5 and CXCR4 genes (HIV-1 co-receptors) in resistance to HIV-1 infection and AIDS development among intravenous drug users.
【24h】

Mutational analysis of the CCR5 and CXCR4 genes (HIV-1 co-receptors) in resistance to HIV-1 infection and AIDS development among intravenous drug users.

机译:静脉吸毒者对CCR5和CXCR4基因(HIV-1共同受体)对HIV-1感染和AIDS产生抵抗力的突变分析。

获取原文
获取原文并翻译 | 示例
           

摘要

We analysed a group of Spanish intravenous drug users and controls to determine the role of mutations at the chemokine receptor-5/HIV-1 cofactor (CCR5), previously implicated in resistance to HIV-1 infection, and CXCR4 genes in susceptibility to HIV-1 infection. The complete coding sequence of both genes was amplified by the polymerase chain reaction from genomic DNA of 50 seropositive slow progressors and 10 long-term non-progressors, and analysed by the single-strand conformation polymorphism technique in a search for mutations. No mutation in CXCR4 was found, and delta ccr5 was the only mutation identified at the CCR5 gene. We genotyped (delta ccr5 allele) 150 HIV-1+ intravenous drug users and 250 healthy controls from the same population (Asturias, Northern Spain). Patients were divided into rapid progressors, presenting an event indicating progression to the acquired immunodeficiency syndrome (AIDS) in the 2 years after infection (100 patients), and slow progressors, remaining asymptomatic for 2-10 years (50 patients). The frequencies of the delta ccr5 allele were 0.105 and 0.040 in controls and HIV-1+ patients, respectively. Eighteen per cent of the controls (45/250) and 8% (12/150) of the patients carried the delta ccr-5 allele (P=0.013). The frequency of delta ccr5 carriers among rapid and slow disease progressors was 3 and 15%, respectively. A highly significant difference was found between rapid progressors and controls (P=0.0014). No patient (0/150) was delta ccr5 homozygous compared with 1% among controls. Thus, the delta ccr5 allele (the only CCR5 mutation found in our HIV-1 patients) was rare among seropositive intravenous drug users, suggesting that the absence of this mutation confers an advantage to the virus when infecting cells in vivo. In addition, patients carrying the delta ccr5 allele tend to show a slow progression towards HIV-1-related disease, remaining asymptomatic for longer periods of time.
机译:我们分析了一组西班牙静脉吸毒者和对照,以确定先前与HIV-1感染抗性有关的趋化因子受体5 / HIV-1辅助因子(CCR5)和CXCR4基因对HIV-的易感性1感染。通过聚合酶链反应从50个血清阳性慢进展者和10个长期非进展者的基因组DNA中扩增了这两个基因的完整编码序列,并通过单链构象多态性技术进行分析以寻找突变。在CXCR4中未发现突变,Δccr5是在CCR5基因上鉴定出的唯一突变。我们对来自同一人群(西班牙北部阿斯图里亚斯)的150名HIV-1 +静脉吸毒者和250名健康对照进行了基因分型(δccr5等位基因)。将患者分为快速进展者,表示感染后2年内进展为获得性免疫缺陷综合症(AIDS)的事件(100例患者)和缓慢进展者,持续2-10年无症状(50例患者)。对照组和HIV-1 +患者的del ccr5等位基因频率分别为0.105和0.040。对照组的18%(45/250)和8%(12/150)的患者携带了delta ccr-5等位基因(P = 0.013)。快速和慢速疾病进展者中δccr5携带者的频率分别为3%和15%。在快速进展者和对照之间发现高度显着差异(P = 0.0014)。没有患者(0/150)是delta ccr5纯合子,而对照组中只有1%。因此,δccr5等位基因(在我们的HIV-1患者中发现的唯一CCR5突变)在血清阳性静脉吸毒者中很少见,这表明在体内感染细胞时,该突变的缺失为病毒带来了优势。另外,携带δccr5等位基因的患者倾向于显示出与HIV-1相关疾病的缓慢进展,并在更长的时间内保持无症状。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号